


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound having the following formula I:




wherein:

'X' represents an α -amino acid group wherein the α -amino group of the amino acid is bound to the $\text{R}_1\text{-O-CO-}$ group and the carboxy group of the amino acid is bound to the $\text{R}_2\text{-CH}_2\text{-CO-(CH}_2)_n\text{-CH(CO}_2\text{H)-NH-}$ group;

'n' is an integer between 1 and 4;

' R_1 ' represents benzyl, t-butyl or 9-fluorenylmethyl; and


'R₂' represents



wherein R₃, R₄, R₅ and R₆ each independently represent lower alkyl or -S⁺R₇R₈, wherein R₇ and R₈ each independently represent lower alkyl or a pharmaceutically and/or veterinarily acceptable derivative thereof.

2. (Original) A compound according to Claim 1 wherein X is an *L*-amino acid group.
3. (Currently amended) A compound according to Claim 1 or 2 wherein X is selected from the group consisting of phenylalanine, glutamine (or an N-substituted derivative thereof), isoleucine, alanine, glycine, tyrosine, proline, serine, lysine and glutamic acid.
4. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein 'n' is 2.
5. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein R₁ is benzyl.


6. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein R₂ represents




7. (Currently amended) A compounds according to claim 1 ~~any one of the preceding claims~~ wherein R₂ represents -S⁺R₇R₈, wherein R₇ and R₈ each independently represent lower alkyl.

8. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein R₃, R₄, R₅, R₆, R₇ and/or R₈ are-CH₃ or -CHCH₂.


9. (Original) A compound according to Claim 1 having the following formula:




10. (Original) A compound according to Claim 1 having the following formula:



11. (Original) A compound according to Claim 1 having the following formula:




12. (Original) A compound according to Claim 1 having the following formula:




13. (Canceled).


14. (Original) A compound according to Claim 1 having the following formula:




15. (Original) A compound according to Claim 1 having the following formula:




16. (Original) A compound according to Claim 1 having the following formula:




17. (Original) A compound according to Claim 1 having the following formula:




18. (Original) A compound according to Claim 1 having the following formula:




19. (Original) A compound according to Claim 1 having the following formula:




20. (Original) A compound according to Claim 1 having the following formula:




21. (Original) A compound according to Claim 1 having the following formula:




22. (Original) A compound according to Claim 1 having the following formula:




23. (Original) A compound according to Claim 1 having the following formula:




24. (Original) A compound according to Claim 1 having the following formula:




25. (Original) A compound according to Claim 1 having the following formula:



26. (Original) A compound according to Claim 1 having the following formula:



27. (Original) A compound according to Claim 1 having the following formula:



28. (Currently amended) A compound according to ~~any one of Claims 1 to 27~~ claim 1 in the form of a bromide salt.

29. (Currently amended) A pharmaceutical formulation comprising a compound according to ~~any one of Claims 1 to 28~~ claim 1 and a pharmaceutically acceptable carrier.

30. (Currently amended) A method for making a compound according to ~~any one of Claims 1 to 28~~ claim 1 comprising the following steps:

(a) reacting an *N*- α -protected (*e.g.* CBZ, FMOC or BOC protected) amino acid *N*-hydroxy-succinimide or *para*-nitrophenyl ester with 6-diazo-5-oxo-L-norleucine, and treating the resulting coupled product with hydrogen bromide; and

(b) reacting the bromomethyl ketone produced in step (a) with dimethyl sulphide, diethyl sulphide or 1,3,4,5-tetra-methyl mercapto-imidazoline-2-thione.

31. (Original) A method according to Claim 30 wherein the *N*- α -protected amino acid *N*-hydroxysuccinimide ester is CBZ, FMOC or BOC protected.

32. (Currently amended) A method according to Claim 30 or 31 wherein step (a) comprises reacting an *N*- α -protected amino acid *N*-hydroxy-succinimide or *para*-nitrophenyl ester with 6-diazo-5-oxo-L-norleucine in the presence of tetrahydrofuran (THF), water and triethylamine followed by reacting the products thereof with hydrogen bromide in the presence of ethyl acetate.

33. (Currently amended) A method according to Claim 31 or 32 wherein the *N*- α -CBZ-protected amino acid *N*-hydroxy-succinimide ester is selected from the group consisting of *N*- α -CBZ-*L*-phenylalanine *N*-hydroxy-succinimide ester, *N*- α -CBZ-*L*-glutamine *N*-hydroxy-succinimide ester, *N*- α -CBZ-*L*-isoleucine *N*-hydroxy-succinimide ester, *N*- α -CBZ-*L*-alaninal *N*-hydroxy-succinimide ester, *N*- α -CBZ-*L*-glycine *N*-hydroxysuccinimide ester, *N*- α -CBZ-*L*-

proline *N*-hydroxy-succinimide ester, *N*- α -CBZ-*L*-serine *N*-hydroxysuccinimide ester, *N*- α -CBZ-*L*-tyrosine *N*-hydroxysuccinimide ester, *N*- α -CBZ-*L*-glutamic acid *N*-hydroxysuccinimide ester, *N*- α -CBZ-*L*-lysine *N*-hydroxysuccinimide ester and *N*- α -CBZ-*L*-tyrosine *para*-nitrophenyl ester.

34-36. (Canceled).

37. (Currently amended) ~~The use according to Claim 35 or 36 wherein the medicament is for treating A method for treating a patient suffering from a disease/disorder selected from the group consisting of fibrosis, scarring, neurodegenerative diseases, autoimmune diseases, thrombosis, proliferative disorders, AIDS, psoriasis, cancer, fibrosis, scarring and inflammation (such as chronic inflammatory diseases), the method comprising administering a composition comprising the compound of Claim 1.~~

38. (Currently amended) The use according to ~~any one of Claims 35 to 37~~ wherein the medicament is for treating cancer.

39-40. (Canceled)

41. (Currently amended) ~~Use of a compound according to any one of Claims 1 to 28 in the preparation of a medicament for preventing or treating A method for treating a patient to prevent or treat rejection of a transplanted organ.~~

42. (Currently amended) ~~A use according to The method of Claim 41 wherein the organ is a heart, lung, kidney or liver.~~

43. (Currently amended) ~~A use according to The method of Claim 41 or 42 wherein the organ is treated prior to transplantation.~~

Applicant : Martin Griffin et al.
Serial No. : To Be Assigned
Filed : Herewith
Page : 14 of 15

Attorney's Docket No.: 11897-007US1/ NOTBA/P30447US

44. (Currently amended) ~~A use according to any one~~ The method of Claims 41 to 43
wherein the organ is treated during and/or after transplantation into a patient.